OMEROS CORPORATION | 4,089 Euro | -0,099 -2,36 % | |
| WKN: A0NBFF ISIN: US6821431029 Ticker-Symbol: 3O8 | Frankfurt | 22.05.13 | 19:33 Uhr |
Branche BiotechnologieAktienmarkt NASDAQ Biotech |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 22.05. | Omeros to Present at Two Upcoming Conferences | 26 | PR Newswire | |
| SEATTLE, May 22, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding... Mehr lesen zu: Omeros to Present at Two Upcoming Conferences | ||||
| 14.05. | Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock | 35 | PR Newswire | |
| SEATTLE, May 14, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER) today reported that it closed the registered direct offering of 3,903,004 shares of its common stock that was announced... Mehr lesen zu: Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock | ||||
| 10.05. | Omeros Q1 loss is 40 cents a share | - | bizjournals | |
| 10.05. | OMEROS CORP - 8-K, Current Report | - | SEC Filings | |
| 10.05. | Omeros Corporation Reports First Quarter 2013 Financial Results | 34 | PR Newswire | |
| SEATTLE, May 10, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting... Mehr lesen zu: Omeros Corporation Reports First Quarter 2013 Financial Results | ||||
| 10.05. | Omeros Announces 3.9M Share Direct Offering of Common Stock at $4.14/Share | 1 | Benzinga.com | |
| 10.05. | Omeros Announces $16.2 Million Registered Direct Offering of Common Stock | 64 | PR Newswire | |
| SEATTLE, May 9, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has agreed to sell 3,903,004 shares of its common stock at a price of $4.14 per share... Mehr lesen zu: Omeros Announces $16.2 Million Registered Direct Offering of Common Stock | ||||
| 01.05. | Omeros Requests Fast Track Designation for OMS824 for the Treatment of Huntington's Disease | 43 | PR Newswire | |
| SEATTLE, May 1, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has requested Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the development... Mehr lesen zu: Omeros Requests Fast Track Designation for OMS824 for the Treatment of Huntington's Disease | ||||
| 30.04. | Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review | 26 | PR Newswire | |
| SEATTLE, April 30, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER) today announced that the European Medicines Agency (EMA) has confirmed that the Company's planned Marketing Authorization Application... Mehr lesen zu: Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review | ||||
| 25.04. | Omeros Reports OMS302 Clinical Data Presented at the Annual ASCRS and ASOA Symposium and Congress | 44 | PR Newswire | |
| SEATTLE, April 25, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER) today reported analyses of Phase 2 and Phase 3 clinical data showing the favorable impact of OMS302 on reducing the incidence... Mehr lesen zu: Omeros Reports OMS302 Clinical Data Presented at the Annual ASCRS and ASOA Symposium and Congress | ||||
| 24.04. | Omeros to Present at the 12th Annual Needham Healthcare Conference | 9 | PR Newswire | |
| SEATTLE, April 24, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding... Mehr lesen zu: Omeros to Present at the 12th Annual Needham Healthcare Conference | ||||
| 19.04. | Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress | 36 | PR Newswire | |
| SEATTLE, April 19, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER) today announced that it will present additional data from recent clinical trials evaluating its ophthalmology product, OMS302... Mehr lesen zu: Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress | ||||
| 19.04. | Omeros files OMS721 orphan drug application with FDA | 2 | Pharma Bus Review | |
| 18.04. | Omeros' OMS721 Files for Orphan Drug Status | - | Zacks | |
| 18.04. | WBB Pounds the Table on Omeros Following Orphan Drug Status, Maintains Strong Buy Rating, $20 Target | 1 | Benzinga.com | |
| 17.04. | Omeros Files Orphan Drug Application with FDA for OMS721 | - | Benzinga.com | |
| 17.04. | Omeros (OMER) Files Orphan Drug Designation App for OMS721 w/ FDA | 1 | StreetInsider.com | |
| 17.04. | Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721 | 27 | PR Newswire | |
| SEATTLE, April 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA)... Mehr lesen zu: Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721 | ||||
| 10.04. | Omeros announces progress in MS research | 2 | bizjournals | |
| 10.04. | Omeros Announces Positive Data for Model for Studying Multiple Sclerosis | 1 | Benzinga.com | |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| CELL THERAPEUTICS | 0,986 | -1,4 % | Cell Therapeutics to Present at Upcoming Investor Conferences |
| AGENUS | 3,27 | +2,51 % | AGENUS INC - 8-K, Current Report |
| SAREPTA THERAPEUTICS | 28,288 | -1,36 % | Sarepta Therapeutics' CEO Presents at 2013 UBS Global Healthcare Conference (Transcript) |
| CYCLACEL | 2,324 | -3,61 % | Cyclacel Pharmaceuticals, Inc. - 8-K, Current Report |
| DYAX | 1,914 | -4,11 % | DYAX CORP - 8-K, Current Report |
